CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kavanagh, A. M.
Right arrow Articles by Hopper, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kavanagh, A. M.
Right arrow Articles by Hopper, J. L.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 1060-1064, May 2005
© 2005 American Association for Cancer Research

Hormone Replacement Therapy, Percent Mammographic Density, and Sensitivity of Mammography

Anne M. Kavanagh1, Jennifer Cawson2, Graham B. Byrnes3, Graham G. Giles4, Georgina Marr4, Bin Tong1, Dorota M. Gertig3 and John L. Hopper3

1 Australian Research Centre in Sex, Health and Society, La Trobe University; 2 St. Vincent's BreastScreen, St. Vincent's Hospital and 3 Centre for Genetic Epidemiology Centre, Department of Public Health, University of Melbourne, Melbourne, Victoria, Australia and 4 Cancer Epidemiology Centre, the Cancer Council of Victoria, Carlton, Victoria, Australia

Requests for reprints: Anne M. Kavanagh, Key Centre for Women's Health in Society, School of Population Health, University of Melbourne, Victoria 3010. Phone: 61-3-8344-7394; Fax: 61-3-9347-9824. E-mail: a.kavanagh{at}unimelb.edu.au

Objective: We examine to what extent the lower mammographic sensitivity found in hormone replacement therapy (HRT) users can be explained by any association of HRT use with higher mammographic density and more difficult to detect cancers.

Methods: We used logistic regression to estimate the odds of a false-negative screen (a breast cancer diagnosed in the 24 months after a negative screening examination) for HRT users and to estimate, and adjust for, mammographic density (measured on a continuous scale, blinded, using a reliable, computer-assisted method), tumor characteristics (size, grade, and morphology), and potential confounders (age, symptom status, family history, and prior screening) among women ages ≥55 years who attended BreastScreen Victoria for first round screening mammography in 1994 and 1995 (1,086 breast cancers) and for subsequent round screening (471 breast cancers) in 1995 and 1996.

Results: After adjusting for confounders, HRT users were more likely to have a false-negative screen [first round: odds ratio (OR), 1.99; 95% confidence interval (95% CI), 1.4-2.9; subsequent round: OR, 2.29; 95% CI, 1.4-3.8]. This effect was modestly attenuated by adjusting for mammographic density (first round: OR, 1.54; 95% CI, 1.0-2.3; subsequent round: OR, 1.97; 95% CI, 1.2-3.3). Adjusting for tumor characteristics resulted in a modest increase in the odds of a false negative at first round but had no effect at subsequent round.

Conclusions: Mammographic density only partly explains the effect of HRT on sensitivity. Further research needs to clarify whether hyperemic breast tissue changes affect cancer detectability in HRT users as well as the possibility that the quality of mammography may be poor in some HRT users.




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
E. J. A. Bowles, D. L. Miglioretti, E. A. Sickles, L. Abraham, P. A. Carney, B. C. Yankaskas, and J. G. Elmore
Accuracy of Short-Interval Follow-Up Mammograms by Patient and Radiologist Characteristics
Am. J. Roentgenol., May 1, 2008; 190(5): 1200 - 1208.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. S. Vaidya
Re: Declines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
J Natl Cancer Inst, April 16, 2008; 100(8): 598 - 599.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. M. Chiarelli, V. A. Kirsh, N. S. Klar, R. Shumak, R. Jong, E. Fishell, M. J. Yaffe, and N. F. Boyd
Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1856 - 1862.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.